SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 12, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Metastatic Leiomyosarcoma
Interventions
DRUG

Mocetinostat

Mocetinostat is taken orally at 70 mg/dose, 3 days per week, during cycle 1. Dose is increased to 90 mg starting at cycle 2.

DRUG

Gemcitabine

Gemcitabine is administered via intravenous infusion at 1,000 mg/m2 at a rate of approximately 10 mg/m2/minute, on days 5 and 12 of every cycle.

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

43210

Ohio State University, Columbus

48109

University of Michigan, Ann Arbor

77030

University of Texas MD Anderson Cancer Center, Houston

02114

Massachusetts General Hospital/Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Sarcoma Alliance for Research through Collaboration

OTHER

NCT02303262 - SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma | Biotech Hunter | Biotech Hunter